About Sora Park

Sora focuses her practice on a variety of life sciences and technology transactions. Her experience includes assisting clients in drafting and negotiating agreements involving the research, development and commercialization of new technologies and products, software licensing, and manufacturing and supply relationships. Sora also provides support on the intellectual property aspects of mergers and acquisitions.

Recent work

• Innovation team of a leading healthcare provider on strategic technology and IP investments and transactions, including transactions involving novel SaMD, AI/ML and data analytic tools to improve healthcare delivery and outcomes.
• Capsida Biotherapeutics on its expanded strategic collaboration with AbbVie to develop genetic medicines for eye diseases, which includes $70 million upfront + equity and up to $595 million in option fees and R&D milestones with potential for future commercial milestones and royalties.
• Capsida Biotherapeutics on its CNS gene therapy collaboration with Prevail Therapeutics for $55 million (upfront + equity) and R&D milestones up to $685 million, as well as tiered royalties and a U.S. co-development/co-commercialization option in exchange for a gross margin share.
• Berkeley Lights (Nasdaq: BLI), a life sciences research tools company, on its acquisition of IsoPlexis (Nasdaq: ISO), a company empowering labs to leverage cells and the proteome, in an all-stock transaction valued at $57.8 million.
• Sairopa on its collaboration, option and license agreement with Exelixis to produce novel oncology therapies.
• Zymergen on its pending $300 million sale to Ginkgo Bioworks—the first-ever sale of a publicly-listed public benefit corporation.
• A patient access and experience-focused mental health company on the development of a digital ecosystem to facilitate patient access to mental healthcare.
• Multiple biopharmaceutical companies on their license, option and collaborations agreements to develop and commercialize drug products and biologics.
• Emerging California-based gene therapy platform on a research collaboration and licensing agreement with a leading biopharmaceutical company to create tissue-targeted gene therapies for three CNS disease targets, including ~$100 million upfront cash and equity payment, $500+ million in option and development milestone payments, and high single-digit royalty payments on future product sales.
• A leading provider of antimicrobial technology on its collaboration for the development and commercialization of antimicrobial products.
• Multiple digital health, medical device, bioengineering, medical technology, and biotechnology companies on their strategic technology and services contracts.
• Walker & Dunlop on the IP aspects of its $744 million acquisition of Alliant Capital, Ltd. and its affiliates, Alliant Strategic Investments and ADC Communities.
• Walker & Dunlop on advice regarding the IP aspects of its investments in technology companies.